-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Zheng Daqing and another heavy-weight generic drug was recently approved for market.
according to the latest review and approval information, Zheng Daqing's blood clotting drug Devashaban tablet first imitation listing application has been in the "review completed - pending certification" state, is expected to be approved for listing soon.
this is the company's second heavy anticoagulant drug since apixaban tablets were approved for market on May 22.
industry analysts said that the two heavyweight products are the first to be approved, its competitiveness in the anticoagulant market will be far ahead.
's super-6 billion-pound drug has huge global market potential Public information shows that Devachaban is a selective coagulation factor Xa inhibitor, developed by Bayer and Johnson and Johnson subsidiary Janssen, as early as 200 It was approved for listing by the European Medicines Agency (EMA) on September 30, 2011 and fda in the United States on July 1, 2011, primarily for the treatment of adult patients with alternative hip or knee replacement surgery to prevent venous thrombosis (VTE).
has been strong since its launch, with sales second only to Apixaban tablets in the 2018 global cardiovascular system.
2016-2018, Xarelto's global sales were $3,278 million, $3,692 million and $6,725 million, respectively, according to public data from the Company.
data source: Public information In the domestic market, Devashaban tablets were approved for listing by the State Drug Administration as early as March 2009 and were included in the national health insurance catalogue in the same year.
the drug's original research for the next decade has been dominating the domestic market, until recently, the news that the first is about to be approved.
Apixaban is the most powerful competitive product of Devachaban, but Apixaban went on the market late, was approved in China in 2013 and was only included in the national health insurance catalogue in 2017, and the first qualifications for both drugs fell into the bag.
in an interview with the International Finance News, an industry insider said that Devashaban, Apishaban generic drugs have been approved for listing, the price is lower than the original research market, which is expected to quickly break the monopoly of the original research in China, for the vast number of patients to provide more drug options.
Studies have shown that 20%-30% of first venous thrombosis events are cancer-related, and if the cancer and thrombosis markets are more relevant in the future, then the domestic demand for these two drugs will also increase significantly, showing that the market potential is huge.
the domestic anticoagulant drug market competition white heat Hua economic market research center data show that in recent years, the domestic anticoagulant drug market size has grown rapidly, the five-year compound growth rate reached 16.19%.
hospital's anticoagulant drug sales in 2018 were 29.2 billion yuan, accounting for 41.35 percent of antithrombotic drug sales.
2018, china's public medical institutions DevaShaban annual sales reached 1.77 billion yuan, up 54.81 percent year-on-year, according to the Minet database.
but the manufacturer is bayer 1, the main sales channel is in the city's public hospitals, accounting for more than 90%.
data source: Minet On July 18, the State Intellectual Property Office issued a decision on the examination of the invalidity declaration, a patent for a preparation by Bayer Devachaban (application number/patent number: 200480035106. X) is invalid.
, Devachaban's compound patent expires in December 2020.
Bayer's Devachaban original development agent was invalidated, providing a unique opportunity for domestic pharmaceutical companies to seize the thrombosis treatment drug market.
although the core patents to expire at the end of next year, but in advance to take the first imitation, enterprises can early layout of the market, do a good job of academic promotion, for market access to do a full preparation.
Today, monopolizing the domestic market for a full decade of original research drugs and generic drugs to seize market share, which domestic pharmaceutical companies can get a piece of the strength? According to drug intelligence network data, in Devashaban tablet generic drugs, there are now 47 enterprises involved, Zheng Dayqing, Xinlitai, Huahai Pharmaceuticals, Yangzijiang Pharmaceuticals and other pharmaceutical companies are in the competition ranks.
industry insiders said that the original drug patent expires will lose the protection of the market, generic drugs can compete with the original drug, in order to maintain the original market share, the original research enterprises may choose to reduce prices.
the two first generic varieties of anticoagulant drugs, in the market share competition advantage is quite a lot.
of all kinds of signs that "snatching the first imitation" is the strategic plan that The Great Day has always adhered to.
of the generic drugs the company currently declares for listing, in addition to Devachaban tablets, 21 varieties (in drug names) have submitted only positive applications for listing, and the review is the fastest progress.
if The Sun is clear to get the first imitation of these drugs, then the 21 varieties will be considered as if they were evaluated through consistency after obtaining the approval for production.
with Devashaban, Apishaban generic drugs have been approved for listing, to lower than the market price of the original research is expected to quickly break the monopoly of the original research in China, for the vast number of patients to provide more drug options.
.